CN1216064C - 6－o－取代的红霉素衍生物的制备方法 - Google Patents

6－o－取代的红霉素衍生物的制备方法 Download PDF

Info

Publication number
CN1216064C
CN1216064C CN008120137A CN00812013A CN1216064C CN 1216064 C CN1216064 C CN 1216064C CN 008120137 A CN008120137 A CN 008120137A CN 00812013 A CN00812013 A CN 00812013A CN 1216064 C CN1216064 C CN 1216064C
Authority
CN
China
Prior art keywords
erythromycin
oxime
add
quinolyl
solution
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Lifetime
Application number
CN008120137A
Other languages
English (en)
Chinese (zh)
Other versions
CN1379780A (zh
Inventor
E·J·斯托纳
M·J·彼得森
顾宜音
R·D·钦克
A·J·科珀
M·N·德斯潘德
T·格里梅
A·R·海特
D·R·希尔
玛格丽特·季萍·徐
S·A·金
M·R·莱恩纳
E·C·李
M·A·麦劳林
H·E·莫尔顿
J·J·纳皮尔
D·J·普拉塔
P·S·拉杰
M·拉斯穆森
D·里利
健－和J·田
S·J·维滕伯格
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
AbbVie Inc
Original Assignee
Abbott Laboratories
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Abbott Laboratories filed Critical Abbott Laboratories
Publication of CN1379780A publication Critical patent/CN1379780A/zh
Application granted granted Critical
Publication of CN1216064C publication Critical patent/CN1216064C/zh
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
    • C07H1/00—Processes for the preparation of sugar derivatives
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
    • C07H17/00—Compounds containing heterocyclic radicals directly attached to hetero atoms of saccharide radicals
    • C07H17/04—Heterocyclic radicals containing only oxygen as ring hetero atoms
    • C07H17/08—Hetero rings containing eight or more ring members, e.g. erythromycins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Biochemistry (AREA)
  • Molecular Biology (AREA)
  • Genetics & Genomics (AREA)
  • Biotechnology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Animal Behavior & Ethology (AREA)
  • Oncology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Communicable Diseases (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Saccharide Compounds (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Low-Molecular Organic Synthesis Reactions Using Catalysts (AREA)
CN008120137A 1999-06-24 2000-06-15 6－o－取代的红霉素衍生物的制备方法 Expired - Lifetime CN1216064C (zh)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US14096899P 1999-06-24 1999-06-24
US60/140,968 1999-06-24

Publications (2)

Publication Number Publication Date
CN1379780A CN1379780A (zh) 2002-11-13
CN1216064C true CN1216064C (zh) 2005-08-24

Family

ID=22493579

Family Applications (1)

Application Number Title Priority Date Filing Date
CN008120137A Expired - Lifetime CN1216064C (zh) 1999-06-24 2000-06-15 6－o－取代的红霉素衍生物的制备方法

Country Status (15)

Country Link
US (1) US6437106B1 (pt)
EP (1) EP1272500B1 (pt)
JP (1) JP4795589B2 (pt)
KR (1) KR100696089B1 (pt)
CN (1) CN1216064C (pt)
AT (1) ATE294809T1 (pt)
AU (1) AU779219B2 (pt)
CA (1) CA2375364C (pt)
DE (1) DE60019976T2 (pt)
ES (1) ES2241619T3 (pt)
HK (1) HK1053659A1 (pt)
IL (1) IL147041A0 (pt)
MX (1) MXPA01013396A (pt)
PT (1) PT1272500E (pt)
WO (1) WO2000078773A2 (pt)

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN102766181A (zh) * 2011-05-06 2012-11-07 上海医药工业研究院 6-o-取代的红霉素衍生物的制备方法

Families Citing this family (89)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6417366B2 (en) * 1999-06-24 2002-07-09 Abbott Laboratories Preparation of quinoline-substituted carbonate and carbamate derivatives
AU2001277764A1 (en) * 2000-08-14 2002-02-25 Taisho Pharmaceutical Co., Ltd. Process for producing erythromycin derivative
TWI246515B (en) 2001-05-30 2006-01-01 Abbott Lab An arylation method for the functionalization of O-allyl erythromycin derivatives
WO2003090761A1 (en) * 2002-04-25 2003-11-06 Abbott Laboratories 9-oxime macrolide antibacterials
US7910558B2 (en) 2002-05-13 2011-03-22 Enanta Pharmaceuticals, Inc. Bridged macrocyclic compounds and processes for the preparation thereof
WO2005070918A1 (en) 2002-05-13 2005-08-04 Enanta Pharmaceuticals, Inc. Process for the preparation of t-11 bicyclic erythromycin derivatives
US7135573B2 (en) 2002-05-13 2006-11-14 Enanta Pharmaceuticals, Inc. Processes for the preparation of O-(6-Pyrazol-1-yl-pyridin-3-ylmethyl)-hydroxylamine
ITMI20021726A1 (it) * 2002-08-01 2004-02-02 Zambon Spa Macrolidi ad attivita' antiinfiammatoria.
EP2772254A3 (en) 2003-03-10 2015-03-11 Optimer Pharmaceuticals, Inc. Novel Antibacterial Agents
CA2443206A1 (en) 2003-09-23 2005-03-23 Ignis Innovation Inc. Amoled display backplanes - pixel driver circuits, array architecture, and external compensation
WO2005067564A2 (en) 2004-01-07 2005-07-28 Enanta Pharmaceuticals, Inc. 6-11 bicyclic erythromycin derivatives
US7384921B2 (en) * 2004-02-20 2008-06-10 Enanta Pharmaceuticals, Inc. Polymorphic forms of 6-11 bicyclic ketolide derivatives
CA2472671A1 (en) 2004-06-29 2005-12-29 Ignis Innovation Inc. Voltage-programming scheme for current-driven amoled displays
US7229972B2 (en) 2004-12-07 2007-06-12 Enanta Pharmaceuticals, Inc. 3,6-Bicyclolides
JP2008522978A (ja) 2004-12-07 2008-07-03 エナンタ ファーマシューティカルズ インコーポレイテッド ３，６−ビシクロライド
WO2006065721A2 (en) 2004-12-13 2006-06-22 Enanta Pharmaceuticals, Inc. 11, 12-lactone bicyclolides
US7312201B2 (en) 2004-12-13 2007-12-25 Enanta Pharmaceuticals, Inc. Tetracyclic bicyclolides
US9799246B2 (en) 2011-05-20 2017-10-24 Ignis Innovation Inc. System and methods for extraction of threshold and mobility parameters in AMOLED displays
US8576217B2 (en) 2011-05-20 2013-11-05 Ignis Innovation Inc. System and methods for extraction of threshold and mobility parameters in AMOLED displays
US9275579B2 (en) 2004-12-15 2016-03-01 Ignis Innovation Inc. System and methods for extraction of threshold and mobility parameters in AMOLED displays
US10012678B2 (en) 2004-12-15 2018-07-03 Ignis Innovation Inc. Method and system for programming, calibrating and/or compensating, and driving an LED display
US10013907B2 (en) 2004-12-15 2018-07-03 Ignis Innovation Inc. Method and system for programming, calibrating and/or compensating, and driving an LED display
US9280933B2 (en) 2004-12-15 2016-03-08 Ignis Innovation Inc. System and methods for extraction of threshold and mobility parameters in AMOLED displays
EP2688058A3 (en) 2004-12-15 2014-12-10 Ignis Innovation Inc. Method and system for programming, calibrating and driving a light emitting device display
US20140111567A1 (en) 2005-04-12 2014-04-24 Ignis Innovation Inc. System and method for compensation of non-uniformities in light emitting device displays
US9171500B2 (en) 2011-05-20 2015-10-27 Ignis Innovation Inc. System and methods for extraction of parasitic parameters in AMOLED displays
US8599191B2 (en) 2011-05-20 2013-12-03 Ignis Innovation Inc. System and methods for extraction of threshold and mobility parameters in AMOLED displays
CA2496642A1 (en) 2005-02-10 2006-08-10 Ignis Innovation Inc. Fast settling time driving method for organic light-emitting diode (oled) displays based on current programming
MX2007011562A (es) * 2005-03-23 2008-03-11 Ind Swift Lab Ltd Un proceso para la preparacion de derivados de la 6-0-metil eritromicina a.
US7517859B2 (en) * 2005-05-04 2009-04-14 Enanta Pharmaceuticals, Inc. Spirocyclic bicyclolides
JP2008540503A (ja) 2005-05-10 2008-11-20 グラクソスミスクライン・イストラジヴァッキ・センタル・ザグレブ・ドルズバ・ゼー・オメイェノ・オドゴヴォルノスティオ 細菌感染症の処置に有用なエーテル結合マクロライド
JP5355080B2 (ja) 2005-06-08 2013-11-27 イグニス・イノベイション・インコーポレーテッド 発光デバイス・ディスプレイを駆動するための方法およびシステム
WO2007036951A2 (en) * 2005-08-31 2007-04-05 Alembic Limited Process to obtain 6-o-methylerythromycin a (clarithromycin)_form ii
CA2518276A1 (en) 2005-09-13 2007-03-13 Ignis Innovation Inc. Compensation technique for luminance degradation in electro-luminance devices
US7595300B2 (en) * 2005-12-13 2009-09-29 Kosan Biosciences Incorporated 7-quinolyl ketolide antibacterial agents
US7407942B2 (en) 2006-03-29 2008-08-05 Emata Pharmaceuticals, Inc 3,6-bridged 9,12-oxolides
WO2007118332A1 (en) 2006-04-19 2007-10-25 Ignis Innovation Inc. Stable driving scheme for active matrix displays
CN100577678C (zh) * 2006-06-19 2010-01-06 中国医学科学院药物研究所 大环内酯类药物双侧链红霉素a衍生物、合成方法和用途
CA2556961A1 (en) 2006-08-15 2008-02-15 Ignis Innovation Inc. Oled compensation technique based on oled capacitance
JP5698979B2 (ja) * 2007-10-25 2015-04-08 センプラ ファーマシューティカルズ，インコーポレイテッド マクロライド系抗菌剤の調製プロセス
CN105616437A (zh) * 2008-10-24 2016-06-01 森普拉制药公司 使用含三唑的大环内酯的生物防御
US9937194B1 (en) 2009-06-12 2018-04-10 Cempra Pharmaceuticals, Inc. Compounds and methods for treating inflammatory diseases
CA2669367A1 (en) 2009-06-16 2010-12-16 Ignis Innovation Inc Compensation technique for color shift in displays
US9384698B2 (en) 2009-11-30 2016-07-05 Ignis Innovation Inc. System and methods for aging compensation in AMOLED displays
US10319307B2 (en) 2009-06-16 2019-06-11 Ignis Innovation Inc. Display system with compensation techniques and/or shared level resources
US9311859B2 (en) 2009-11-30 2016-04-12 Ignis Innovation Inc. Resetting cycle for aging compensation in AMOLED displays
CA2688870A1 (en) 2009-11-30 2011-05-30 Ignis Innovation Inc. Methode and techniques for improving display uniformity
CN108310000A (zh) 2009-09-10 2018-07-24 森普拉制药公司 治疗疟疾、结核病和mac疾病的方法
US10996258B2 (en) 2009-11-30 2021-05-04 Ignis Innovation Inc. Defect detection and correction of pixel circuits for AMOLED displays
US8803417B2 (en) 2009-12-01 2014-08-12 Ignis Innovation Inc. High resolution pixel architecture
CA2687631A1 (en) 2009-12-06 2011-06-06 Ignis Innovation Inc Low power driving scheme for display applications
US10163401B2 (en) 2010-02-04 2018-12-25 Ignis Innovation Inc. System and methods for extracting correlation curves for an organic light emitting device
CA2692097A1 (en) 2010-02-04 2011-08-04 Ignis Innovation Inc. Extracting correlation curves for light emitting device
US9881532B2 (en) 2010-02-04 2018-01-30 Ignis Innovation Inc. System and method for extracting correlation curves for an organic light emitting device
US10089921B2 (en) 2010-02-04 2018-10-02 Ignis Innovation Inc. System and methods for extracting correlation curves for an organic light emitting device
US10176736B2 (en) 2010-02-04 2019-01-08 Ignis Innovation Inc. System and methods for extracting correlation curves for an organic light emitting device
US20140313111A1 (en) 2010-02-04 2014-10-23 Ignis Innovation Inc. System and methods for extracting correlation curves for an organic light emitting device
CA2696778A1 (en) 2010-03-17 2011-09-17 Ignis Innovation Inc. Lifetime, uniformity, parameter extraction methods
EP3009442B1 (en) 2010-03-22 2019-06-19 Cempra Pharmaceuticals, Inc. Crystalline forms of a macrolide, and uses therefor
DK2571506T3 (en) 2010-05-20 2017-08-28 Cempra Pharmaceuticals Inc PROCEDURES FOR THE MANUFACTURE OF MACROLIDES AND KETOLIDES AND INTERMEDIATES
US9815863B2 (en) 2010-09-10 2017-11-14 Cempra Pharmaceuticals, Inc. Hydrogen bond forming fluoro ketolides for treating diseases
US8907991B2 (en) 2010-12-02 2014-12-09 Ignis Innovation Inc. System and methods for thermal compensation in AMOLED displays
CN102766089A (zh) * 2011-05-06 2012-11-07 上海医药工业研究院 3-(3-喹啉基)-2-丙烯-1-卤代物及其制备方法
US9530349B2 (en) 2011-05-20 2016-12-27 Ignis Innovations Inc. Charged-based compensation and parameter extraction in AMOLED displays
US9466240B2 (en) 2011-05-26 2016-10-11 Ignis Innovation Inc. Adaptive feedback system for compensating for aging pixel areas with enhanced estimation speed
EP3293726B1 (en) 2011-05-27 2019-08-14 Ignis Innovation Inc. Systems and methods for aging compensation in amoled displays
US9324268B2 (en) 2013-03-15 2016-04-26 Ignis Innovation Inc. Amoled displays with multiple readout circuits
US10089924B2 (en) 2011-11-29 2018-10-02 Ignis Innovation Inc. Structural and low-frequency non-uniformity compensation
US8937632B2 (en) 2012-02-03 2015-01-20 Ignis Innovation Inc. Driving system for active-matrix displays
RU2658050C2 (ru) 2012-03-27 2018-06-19 Семпра Фармасьютикалз, Инк. Парентеральные составы для введения макролидных антибиотиков
US9747834B2 (en) 2012-05-11 2017-08-29 Ignis Innovation Inc. Pixel circuits including feedback capacitors and reset capacitors, and display systems therefore
US8922544B2 (en) 2012-05-23 2014-12-30 Ignis Innovation Inc. Display systems with compensation for line propagation delay
US9786223B2 (en) 2012-12-11 2017-10-10 Ignis Innovation Inc. Pixel circuits for AMOLED displays
US9336717B2 (en) 2012-12-11 2016-05-10 Ignis Innovation Inc. Pixel circuits for AMOLED displays
US9830857B2 (en) 2013-01-14 2017-11-28 Ignis Innovation Inc. Cleaning common unwanted signals from pixel measurements in emissive displays
US9171504B2 (en) 2013-01-14 2015-10-27 Ignis Innovation Inc. Driving scheme for emissive displays providing compensation for driving transistor variations
EP3043338A1 (en) 2013-03-14 2016-07-13 Ignis Innovation Inc. Re-interpolation with edge detection for extracting an aging pattern for amoled displays
JP6426696B2 (ja) 2013-03-14 2018-11-21 センプラ ファーマシューティカルズ，インコーポレイテッド 呼吸器疾患の治療のための方法および製剤
CA2907085A1 (en) 2013-03-15 2014-09-18 Cempra Pharmaceuticals, Inc. Convergent processes for preparing macrolide antibacterial agents
CN105144361B (zh) 2013-04-22 2019-09-27 伊格尼斯创新公司 用于oled显示面板的检测系统
DE112014003719T5 (de) 2013-08-12 2016-05-19 Ignis Innovation Inc. Kompensationsgenauigkeit
US9761170B2 (en) 2013-12-06 2017-09-12 Ignis Innovation Inc. Correction for localized phenomena in an image array
US9741282B2 (en) 2013-12-06 2017-08-22 Ignis Innovation Inc. OLED display system and method
US9502653B2 (en) 2013-12-25 2016-11-22 Ignis Innovation Inc. Electrode contacts
DE102015206281A1 (de) 2014-04-08 2015-10-08 Ignis Innovation Inc. Anzeigesystem mit gemeinsam genutzten Niveauressourcen für tragbare Vorrichtungen
CA2879462A1 (en) 2015-01-23 2016-07-23 Ignis Innovation Inc. Compensation for color variation in emissive devices
CA2889870A1 (en) 2015-05-04 2016-11-04 Ignis Innovation Inc. Optical feedback system
CA2892714A1 (en) 2015-05-27 2016-11-27 Ignis Innovation Inc Memory bandwidth reduction in compensation system
CA2900170A1 (en) 2015-08-07 2017-02-07 Gholamreza Chaji Calibration of pixel based on improved reference values

Family Cites Families (25)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ZA695765B (en) 1968-08-29 1971-03-31 Lilly Co Eli Erythromycylamine and process for preparing same
GB1344629A (en) 1970-09-30 1974-01-23 Lilly Industries Ltd Erythromycin azine derivatives
US4331803A (en) 1980-06-04 1982-05-25 Taisho Pharmaceutical Co., Ltd. Novel erythromycin compounds
JPS60214796A (ja) 1984-04-06 1985-10-28 Taisho Pharmaceut Co Ltd ６−０−メチルエリスロマイシン類の製法
JPS61103890A (ja) 1984-10-26 1986-05-22 Taisho Pharmaceut Co Ltd ６−０−メチルエリスロマイシンａ誘導体
US4670549A (en) 1985-03-18 1987-06-02 Taisho Pharmaceutical Co., Ltd. Method for selective methylation of erythromycin a derivatives
JPS61229895A (ja) 1985-04-03 1986-10-14 Nippon Zeon Co Ltd 保護化デス−ｎ−メチルエリスロマイシン誘導体
DE3782994T2 (de) 1986-09-18 1993-04-08 Taisho Pharmaceutical Co Ltd Erythromycin-a-derivate und verfahren zu ihrer herstellung.
KR960000434B1 (ko) 1986-12-17 1996-01-06 다이쇼 세이야꾸 가부시끼가이샤 에리스로마이신 a유도체 및 그의 제조 방법
JP2751385B2 (ja) 1988-05-19 1998-05-18 大正製薬株式会社 エリスロマイシンａオキシム及びその塩の製造方法
US5872229A (en) 1995-11-21 1999-02-16 Abbott Laboratories Process for 6-O-alkylation of erythromycin derivatives
US5719272A (en) 1996-04-02 1998-02-17 Abbott Laboratories 2'-protected 3'-dimethylamine, 9-etheroxime erythromycin A derivatives
US5837829A (en) 1996-04-02 1998-11-17 Abbott Laboratories 9-oximesilyl erythromycin a derivatives
US5808017A (en) 1996-04-10 1998-09-15 Abbott Laboratories Process for preparing erythromycin A oxime
NZ332320A (en) 1996-05-07 2000-07-28 Abbott Lab 6-0-substituted erythromycin compounds and medicaments
CN100441591C (zh) 1996-09-04 2008-12-10 艾博特公司 酮基内酯类化合物，其用途和制备方法以及药用组合物
UA51730C2 (uk) 1996-09-04 2002-12-16 Ебботт Лабораторіз 6-o-заміщені кетоліди з антибактеріальною активністю, спосіб їх одержання (варіанти), фармацевтична композиція та спосіб регулювання бактеріальної інфекції у ссавців
US5864023A (en) 1997-02-13 1999-01-26 Abbott Laboratories 3'-N'oxide, 3'-n-dimethylamine, 9-oxime erythromycin a derivatives
JP2001513555A (ja) * 1997-08-28 2001-09-04 イーライ・リリー・アンド・カンパニー 非リウマチ様関節炎の処置方法
ZA987689B (en) 1997-09-02 1999-02-24 Abbott Lab 3-descladinose 6-O substituted erythromycin derivatives
US5929219A (en) 1997-09-10 1999-07-27 Abbott Laboratories 9-hydrazone and 9-azine erythromycin derivatives and a process of making the same
PT1025114E (pt) 1997-09-30 2004-07-30 Abbott Lab Derivados de eritromicina-cetolido 6-o-substituido 3'-n-modificados possuindo actividade antibacteriana
AR015986A1 (es) 1997-10-29 2001-05-30 Abbott Lab Derivados de eritromicina puenteados en 6,11, composiciones farmaceuticas que los contienen, su uso para la manufactura de un medicamento y procedimientospara su preparacion
US5852180A (en) 1997-11-17 1998-12-22 Abbott Laboratories Chemical synthesis of 6-O-alkyl erythromycin A
US5892008A (en) 1997-12-16 1999-04-06 Abbott Laboratories Process for the preparation of 6-O-methyl erythromycin a using 9-hydroxy erythromycin derivatives

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN102766181A (zh) * 2011-05-06 2012-11-07 上海医药工业研究院 6-o-取代的红霉素衍生物的制备方法

Also Published As

Publication number Publication date
ATE294809T1 (de) 2005-05-15
WO2000078773A3 (en) 2001-02-22
AU5742900A (en) 2001-01-09
DE60019976D1 (de) 2005-06-09
US6437106B1 (en) 2002-08-20
DE60019976T2 (de) 2006-02-16
CA2375364C (en) 2008-11-25
IL147041A0 (en) 2002-08-14
CA2375364A1 (en) 2000-12-28
KR100696089B1 (ko) 2007-03-20
AU779219B2 (en) 2005-01-13
MXPA01013396A (es) 2002-07-30
HK1053659A1 (en) 2003-10-31
EP1272500A2 (en) 2003-01-08
EP1272500B1 (en) 2005-05-04
ES2241619T3 (es) 2005-11-01
KR20020033644A (ko) 2002-05-07
WO2000078773A2 (en) 2000-12-28
JP2003502432A (ja) 2003-01-21
JP4795589B2 (ja) 2011-10-19
PT1272500E (pt) 2005-09-30
CN1379780A (zh) 2002-11-13

Similar Documents

Publication Publication Date Title
CN1216064C (zh) 6－o－取代的红霉素衍生物的制备方法
CN1035675C (zh) 制备n4－酰基－5′－脱氧－5－氟胞苷衍生物的新方法
CN1179970C (zh) 嘌呤衍生物
CN1052984C (zh) 新的红霉素衍生物、其制备方法及其作为药物的应用
CN1148189C (zh) 作为tnf抑制剂和pdc-iv抑制剂的喹啉甲酰胺类化合物
CN1137275A (zh) 具有免疫抑制活性的o-芳基、o-烷基、o-烯基和o-炔基大环内酯物
CN1373767A (zh) 酮式大环内酯抗菌剂
CN1131948A (zh) 吡唑并[1，5-a]嘧啶衍生物
CN1237165A (zh) 法呢基蛋白转移酶的三环抑制剂
CN1756759A (zh) 制备c－芳基葡糖苷sglt2抑制剂的方法
CN1114959A (zh) 有7-(4-氨基甲基-3-肟)吡咯烷取代基的新喹啉羧酸衍生物和其制法
CN1337950A (zh) 2－氧代喹啉化合物及其药物用途
CN1090581A (zh) 红霉素的新衍生物和它们的制备方法及其作为药物的应用
CN1315949A (zh) 帕罗西汀甲磺酸盐
CN1464880A (zh) 具有抗细菌活性的新的大环内酯
CN1278266A (zh) 6,11－桥连红霉素衍生物
CN1281615C (zh) 从9a－氮杂大环内酯类衍生的新3,6－半缩酮类
CN1271363A (zh) 具有抗菌活性的3’－n－修饰的6－o－取代的红霉素酮基内酯衍生物
CN1856486A (zh) 取代的内酰胺和它们作为抗癌剂的用途
CN1050719A (zh) 表鬼臼毒素阿卓糖苷衍生物的制备方法
CN1122031C (zh) 用作法呢基蛋白转移酶抑制剂的取代的苯并芳庚并吡啶衍生物
CN1663952A (zh) 喹啉取代的碳酸酯和氨基甲酸酯衍生物
CN1278825A (zh) 可用于稳定微管的珊瑚素和五加苷素
CN1237164A (zh) 用作法呢基－蛋白转移酶抑制剂的化合物
CN1326461A (zh) 减数分裂调控化合物

Legal Events

Date Code Title Description
C10 Entry into substantive examination
SE01 Entry into force of request for substantive examination
C06 Publication
PB01 Publication
C14 Grant of patent or utility model
GR01 Patent grant
C56 Change in the name or address of the patentee

Owner name: ABBOTT PHARMACEUTICAL CO., LTD.

Free format text: FORMER NAME: ABBOTT LAB

CP03 Change of name, title or address

Address after: Illinois State

Patentee after: Abbott GmbH. & Co. Kg

Address before: Illinois State

Patentee before: ABBOTT LABORATORIES

ASS Succession or assignment of patent right

Owner name: ABBVIE COMPANY

Free format text: FORMER OWNER: ABBOTT GMBH. + CO. KG

Effective date: 20130617

C41 Transfer of patent application or patent right or utility model
TR01 Transfer of patent right

Effective date of registration: 20130617

Address after: Illinois State

Patentee after: ABBVIE company

Address before: Illinois State

Patentee before: Abbott GmbH. & Co. Kg

CX01 Expiry of patent term

Granted publication date: 20050824

CX01 Expiry of patent term